NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
EXAS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. EXAS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, EXAS is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.36% | ||
ROE | -42.83% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 69.55% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.97 | ||
Debt/FCF | 87.7 | ||
Altman-Z | 0.79 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.15 | ||
Quick Ratio | 1.92 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 271.41 | ||
EV/EBITDA | 248.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:EXAS (4/21/2025, 3:49:04 PM)
43.17
+1.59 (+3.82%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.91 | ||
P/FCF | 271.41 | ||
P/OCF | 38.09 | ||
P/B | 3.34 | ||
P/tB | N/A | ||
EV/EBITDA | 248.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.36% | ||
ROE | -42.83% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 69.55% | ||
FCFM | 1.07% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.97 | ||
Debt/FCF | 87.7 | ||
Debt/EBITDA | 65.54 | ||
Cap/Depr | 84.24% | ||
Cap/Sales | 6.56% | ||
Interest Coverage | N/A | ||
Cash Conversion | 591.13% | ||
Profit Quality | N/A | ||
Current Ratio | 2.15 | ||
Quick Ratio | 1.92 | ||
Altman-Z | 0.79 |